Literature DB >> 22706990

Residue 81 confers a restricted C-terminal peptide binding motif in HLA-B*44:09.

Trevor Huyton1, Heike Schumacher, Rainer Blasczyk, Christina Bade-Doeding.   

Abstract

Knowledge about the magnitude of individual polymorphism is a critical part in understanding the complexity of comprehensive mismatching. HLA-B*44:09 differs from the highly frequent HLA-B*44:02 allele by amino acid exchanges at residues 77, 80, 81, 82 and 83. We aimed to identify the magnitude of these mismatches on the features of HLA-B*44:09 bound peptides since residues 77, 80 and 81 comprise part of the F pocket which determines sequence specificity at the pΩ position of the peptide. Using soluble HLA technology we determined >200 individual (nonduplicate) self-peptides from HLA-B*44:09 and compared their features with that of the published peptide features of HLA-B*44:02. Both alleles illustrate an anchor motif of E at p2. In contrast to the C-terminal peptide binding motif of B*44:02 (W, F, Y or L), B*44:09-derived peptides are restricted predominantly to L or F. The source of peptides for both alleles is identical (LCL 721.221 cells) allowing us to identify 23 shared peptides. The majority of these peptides however contained the restricted B*44:09 anchor motif of F or L at the pΩ position. Molecular modelling based on the B*44:02 structure highlights that the differences of the C-terminal peptide anchor between both alleles can be explained primarily by the B*44:02(81Ala) > B*44:09(81Leu) polymorphism which restricts the size of the amino acid that can be accommodated in the F pocket of B*44:09. These results highlight that every amino acid substitution has an impact of certain magnitude on the alleles function and demonstrate how surrounding residues orchestrate peptide specificity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22706990     DOI: 10.1007/s00251-012-0625-1

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  24 in total

1.  Position 45 influences the peptide binding motif of HLA-B*44:08.

Authors:  Soumya Badrinath; Trevor Huyton; Heike Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  Immunogenetics       Date:  2011-10-19       Impact factor: 2.846

2.  HLA-B27 polymorphism at position 116 critically influences the association with TAP/tapasin, intracellular trafficking and conformational homodimers formation.

Authors:  M A Blanco-Gelaz; B Suárez-Alvarez; R Díaz-Peña; C López-Larrea
Journal:  Mol Immunol       Date:  2009-01-23       Impact factor: 4.407

3.  Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA-B44 supertype.

Authors:  Nina Hillen; Gabor Mester; Claudia Lemmel; Andreas O Weinzierl; Margret Müller; Dorothee Wernet; Jörg Hennenlotter; Arnulf Stenzl; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Eur J Immunol       Date:  2008-11       Impact factor: 5.532

4.  T cell allorecognition via molecular mimicry.

Authors:  Whitney A Macdonald; Zhenjun Chen; Stephanie Gras; Julia K Archbold; Fleur E Tynan; Craig S Clements; Mandvi Bharadwaj; Lars Kjer-Nielsen; Philippa M Saunders; Matthew C J Wilce; Fran Crawford; Brian Stadinsky; David Jackson; Andrew G Brooks; Anthony W Purcell; John W Kappler; Scott R Burrows; Jamie Rossjohn; James McCluskey
Journal:  Immunity       Date:  2009-12-18       Impact factor: 31.745

5.  The composition of the F pocket in HLA-A*74 generates C-terminal promiscuity among its bound peptides.

Authors:  C Bade-Doeding; T Huyton; B Eiz-Vesper; R Blasczyk
Journal:  Tissue Antigens       Date:  2011-07-18

Review 6.  Monoclonal antibodies for analysis of the HLA system.

Authors:  F M Brodsky; P Parham; C J Barnstable; M J Crumpton; W F Bodmer
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

Review 7.  Proteasome and class I antigen processing and presentation.

Authors:  M P Belich; J Trowsdale
Journal:  Mol Biol Rep       Date:  1995       Impact factor: 2.316

8.  MASCOT: multiple alignment system for protein sequences based on three-way dynamic programming.

Authors:  M Hirosawa; M Hoshida; M Ishikawa; T Toya
Journal:  Comput Appl Biosci       Date:  1993-04

9.  HLA class I allele promiscuity revisited.

Authors:  Xiangyu Rao; Ilka Hoof; Ana Isabel C A Fontaine Costa; Debbie van Baarle; Can Keşmir
Journal:  Immunogenetics       Date:  2011-06-22       Impact factor: 2.846

10.  Amino acid 95 causes strong alteration of peptide position Pomega in HLA-B*41 variants.

Authors:  Christina Bade-Doeding; David S DeLuca; Axel Seltsam; Rainer Blasczyk; Britta Eiz-Vesper
Journal:  Immunogenetics       Date:  2007-02-10       Impact factor: 2.846

View more
  5 in total

1.  A Micropolymorphism Altering the Residue Triad 97/114/156 Determines the Relative Levels of Tapasin Independence and Distinct Peptide Profiles for HLA-A(*)24 Allotypes.

Authors:  Soumya Badrinath; Heike Kunze-Schumacher; Rainer Blasczyk; Trevor Huyton; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-12-04       Impact factor: 4.818

2.  Soluble HLA technology as a strategy to evaluate the impact of HLA mismatches.

Authors:  Heike Kunze-Schumacher; Rainer Blasczyk; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-09-01       Impact factor: 4.818

Review 3.  HLA-E: a novel player for histocompatibility.

Authors:  Thomas Kraemer; Rainer Blasczyk; Christina Bade-Doeding
Journal:  J Immunol Res       Date:  2014-10-20       Impact factor: 4.818

4.  HLA-E: Presentation of a Broader Peptide Repertoire Impacts the Cellular Immune Response-Implications on HSCT Outcome.

Authors:  Thomas Kraemer; Alexander A Celik; Trevor Huyton; Heike Kunze-Schumacher; Rainer Blasczyk; Christina Bade-Döding
Journal:  Stem Cells Int       Date:  2015-08-12       Impact factor: 5.443

5.  The diversity of the HLA-E-restricted peptide repertoire explains the immunological impact of the Arg107Gly mismatch.

Authors:  Alexander A Celik; Thomas Kraemer; Trevor Huyton; Rainer Blasczyk; Christina Bade-Döding
Journal:  Immunogenetics       Date:  2015-11-09       Impact factor: 2.846

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.